Pharmaceutical polymorphisms and its influence on the dissolution profile of two pioglitazone brands

Eduardo Lozano GuzmÃ¡n; SaÃºl Alejandro Aguirre RenterÃ­a; MarÃ­a Guadalupe Nieto Pescador; Maribel Cervantes Flores; Ãngel Antonio VÃ©rtiz HernÃ¡ndez; Francisco Javier Moreno Cruz

doi:10.5897/AJPP2019.5079

African Journal of
Pharmacy and Pharmacology

Abbreviation: Afr. J. Pharm. Pharmacol.
Language: English
ISSN: 1996-0816
DOI: 10.5897/AJPP
Start Year: 2007
Published Articles: 2298

Full Length Research Paper

Pharmaceutical polymorphisms and its influence on the dissolution profile of two pioglitazone brands

Eduardo Lozano GuzmÃ¡n

Eduardo Lozano GuzmÃ¡n
Pharmacognosy Laboratory,Faculty of Chemical Sciences, Juarez Durango State University, Mexico.
Search for this author on:
Google Scholar

SaÃºl Alejandro Aguirre RenterÃa

SaÃºl Alejandro Aguirre RenterÃa
Pharmacognosy Laboratory,Faculty of Chemical Sciences, Juarez Durango State University, Mexico.
Search for this author on:
Google Scholar

MarÃa Guadalupe Nieto Pescador

MarÃa Guadalupe Nieto Pescador
Pharmacognosy Laboratory,Faculty of Chemical Sciences, Juarez Durango State University, Mexico.
Search for this author on:
Google Scholar

Maribel Cervantes Flores

Maribel Cervantes Flores
Pharmacognosy Laboratory,Faculty of Chemical Sciences, Juarez Durango State University, Mexico.
Search for this author on:
Google Scholar

Ãngel Antonio VÃ©rtiz HernÃ¡ndez

Ãngel Antonio VÃ©rtiz HernÃ¡ndez
Technology and health laboratory, Academic Coordination Altiplano Region, Autonomy University of San Luis, Potosi, Mexico.
Search for this author on:
Google Scholar

Francisco Javier Moreno Cruz

Francisco Javier Moreno Cruz
Pharmacognosy Laboratory,Faculty of Chemical Sciences, Juarez Durango State University, Mexico.
Search for this author on:
Google Scholar

Article Number - 76940AD62040
Vol.13(16), pp. 273-279 , October 2019
https://doi.org/10.5897/AJPP2019.5079

Received: 20 September 2019
Accepted: 09 October 2019
Published: 31 October 2019

References

Aubuchon S, Gracia-Del Rió C (2018). Determinación mediante DSC y DSC-Raman de polimorfismos en principios activos farmacéuticos. [Report], XIV Reunión Anual de la Asociación Argentina de Cristalografía, Argentina.

Chengcheng Z, Adam JM (2017). A Newly Discovered Racemic Compound of Pioglitazone Hydrochloride Is More Stable than the Commercial Conglomerate. Crystal Growth and Design 17(2):414-417. Crossref

De Salvi BS (2011). Polimorfismo em medicamentos genéricos e similares. Master Thesis, Universida de Estadual Paulista, Brazil,.

Du Y, Xue J (2016). Investigation of polymorphism and cocrystallization of active pharmaceutical ingredients using vibrational spectroscopic techniques. Current Pharmaceutical Design 22(32):4917-4928. Crossref

Fuentes NI, Rubio CK, Hernández PL, Portilla MB, Aguilar AE (2006). Estudios de perfiles de disolución, calorimetría diferencial de barrido y tamaño de partícula como elementos para determinar la calidad de materias primas. Revista Mexicana de Ciencias Farmacéuticas 37(4):43-57.

García BM (2013). Desarrollo y aplicación de la espectroscopia Raman amplificada en superficie (sers) para estudio no destructivo de pintura novohispana. [Thesis] Universidad Nacional Autónoma de México. México.

Garland R (2007). Pharmaceutical polymorphism. Cuadernos Medico Sociales, Chile 47(3):191-199.

Gonzalez MA, Castro A, Melendez L (2015). Identificación de las estructuras polimórficas en comprimidos comerciales de glibenclamida. Revista Iberoamericana de Producción Académica y Gestión Educativa 2(4):1-16.

Hiendrawan S, Widjojokusumo E, Veriansyah B, Tjandrawinata RR (2017). Pharmaceutical salts of carvedilol: polymorphism and physicochemical properties. AAPS PharmSciTech 18(4):1417-1425. Crossref

Islán ÁPM, Montes EM (2006). Polimorfismo farmacéutico: repercusiones industriales y farmacocinéticas. Offarm: farmacia y sociedad 25:94-100.

Lara JC, López AB (2017). Importancia de las sales orgánicas en la industria farmacéutica. Revista Mexicana de Ciencias Farmaceuticas 48(1):18-42.

NOM-177-SSA1-2013. Official Mexican Standard that establishes the tests and procedures to demonstrate that a medicine is interchangeable.

Prohens R, Puigjaner C (2007).Polimorfismo en la industria farmacéutica. El Farmacéutico 373:58-68.

Sachinkumar P, Atmaram P, Sunit KS (2012). Effect of Additives on the Physicochemical and Drug Release Properties of Pioglitazone Hydrochloride Spherical Agglomerates. Tropical Journal of Pharmaceutical Research 11(1):18-27. Crossref

Sánchez E, Jung H, Yépez L, Hernández AV (2007). Relevancia del polimorfismo en el área farmacéutica. Revista Mexicana de Ciencias Farmaceuticas 38(2):57-76.

Sharma A, Mishra R, Tandon P (2011). Polymorphism in Pharmaceutical Compounds. Advancements and Futuristic Trends in Material Science pp. 39-48.

Sugita M, Kataoka M, Sugihara M, Takeuchi S, Yamashita S (2014). Effect of excipients on the particle size of precipitated pioglitazone in the gastrointestinal tract: Impact on bioequivalence. The AAPS Journal 16(5):1119-1127. Crossref

Tao M, Sun H, Wang Z, Cui P, Wang J (2013). Correlation of solubility of pioglitazone hydrochloride in different binary solvents. Fluid Phase Equilibria 352:14-21. Crossref

Tao-Zhao W, Junbo G, Hongxun H, Jingkang W (2013). Determination of the Solubility, Dissolution Enthalpy and Entropy of Pioglitazone Hydrochloride (Form II) in Different Pure Solvents. Industrial and Engineering Chemistry Research 52:3036-3041.

Vértiz BJ, Ávila R, Terrones R, Camacho LA, Rangel LA, Campos CI, Vértiz HA (2014). Clorhidrato de pioglitazona: una perspectiva analítico-instrumental por espectroscopia Raman y HPLC. Revista de Investigación Clínica 66:351-358.

Zhou Y, Wang J, Xiao Y, Wang T, Huang X (2018). The Effects of Polymorphism on Physicochemical Properties and Pharmacodynamics of Solid Drugs. Current Pharmaceutical Design 24(21):2375-2382. Crossref